Modified HEART as Rule Out for Suspected ACS

Chest Pain Clinical Trial

Official title:

Does Modified Heart Score Incorporating Undetectable and 99th Percentile High Sensitivity Troponin T Limits Improve Early, Safe Discharge for Suspected Acute Coronary Syndromes

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03619733
• Other study ID #: AintreeNHS
• Status: Recruiting
• Start date: June 1, 2018
• Est. completion date: December 1, 2018

Study information

• Verified date: August 2018
• Source: Aintree University Hospitals NHS Foundation Trust
• Contact: aleem khand
• Phone: 00441516002720
• Email: akhand31[@]aol.com
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Validation of modified HEART score as a rule-out criterion for MACE at 6 weeks: a 2 centre prospective observational cohort with a direct comparison to TIMI, GRACE and high sensitive troponin T at limits of detection

Detailed description:

The HEART score, as defined previously by Backus et al1, is a risk score specifically developed for acute chest pain/ suspected acute coronary syndrome. The conventional scoring system for the troponin component of HEART is as follows: Troponin <99th percentile =0 (in the case of Hstn T [Roche} 14ng/l, 99th percentile up to X3 URL (99th percentile)= 1 (HSTN T =14-42ng/L, >x3 URN =2 (HSTN T >42ng/l).

We have previously defined that the optimal rule-out strategy for suspected acute coronary syndromes may well be a modified HEART score in a single centre study. This study is to prospectively validate the use of this score in a prospective unselected cohort of patients with possible acute coronary syndrome at 2 large secondary care centres

Description:

Validation of modified HEART score as a rule-out criterion for MACE at 6 weeks: a 2 centre prospective observational cohort with a direct comparison to TIMI, GRACE and high sensitive troponin T at limits of detection

Detailed description:

The HEART score, as defined previously by Backus et al1, is a risk score specifically developed for acute chest pain/ suspected acute coronary syndrome. The conventional scoring system for the troponin component of HEART is as follows: Troponin <99th percentile =0 (in the case of Hstn T [Roche} 14ng/l, 99th percentile up to X3 URL (99th percentile)= 1 (HSTN T =14-42ng/L, >x3 URN =2 (HSTN T >42ng/l).

the investigators previously defined that the optimal rule-out strategy for suspected acute coronary syndromes may well be a modified HEART score in a single centre study. This study is to prospectively validate the use of this score in a prospective unselected cohort of patients with possible acute coronary syndrome at 2 large secondary care centres. The second centre (Royal Liverpool University Hospital) was external to where the initial cohort of 1642 patients were assessed that defined modified HEART as the optimal score.

The modified HEART score is as follows: HEART score can be re-calibrated (modified HEART) to undetectable hstnT and 99th percentile limits (<5= 0, ≥5-14=1, >14=2).

Troponin (HSTnT) Roche (elecsys) >14ng/l 2 5-14ng/l 1 <5ng/l 0

This 2 centre study will enrol consecutive patients with suspected acute coronary syndrome (defined as physician suspicion of ischaemic chest pain resulting in sampling of High sensitive troponin and undertaking an electrocardiogram at presentation).

For all troponin positive patients (HSTnT>14ng/l) the diagnosis will be adjudicated centrally with at least 2 'blinded' clinicians. The outcome will be MACE at 6 weeks. MACE will be defined by acute myocardial infarction, urgent or emergency coronary revascularisation and all cause death.

Power calculations (provided by clinical trials, university of Liverpool):

Assuming:

Prevalence of MACE events in the population with suspected ACS is 12.5% (as in MACROS) The anticipated sensitivity is 0.98 The acceptable value for the 95% confidence interval for sensitivity is 0.95 The power of the study is 80%

Then the number of events needed would be approximately 150. Thus 150/0.125 = 1200 suspected ACS admission would need to be enrolled

The study has been assessed by research boards at both hospitals and has been registered as an audit, with the primary aim of quality control of a novel accelerated chest pain pathway that has been recently implemented at both hospitals. The study does not require individualised patient consent and is supported by the Caldicott Guardian.

Secondary aims of the study are to compare the performance of modified HEART score with modified TIMI < or equal to 1 or 0 and modified GRACE score < or equal to 75 in terms of rule out for MACE at 6 weeks The investigators compare the 'performance' of modified HEART with the use of undetectable HSTnT <5ng/l (combined with a nonischaemic ECG). The latter is part of the recently adopted chest pain pathway at both recruiting hospitals with clear guidance of discharge at presentation for patients with chest pain who have an undetectable HSTnT and nonischaemic ECG. Therefore it will allow the research team to compare modified HEART virtual discharge with actual (rather than virtual) discharge for an approach based on undetectable HSTnT.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1100
• Est. completion date: December 1, 2018
• Est. primary completion date: September 1, 2018
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:consecutive presentations to A&E at 2 major urban hospital swith chest pain that the clinicans feel warrants a biomarker check for myocyte necrosis (high sensitive troponin) and presentation ECG

Exclusion Criteria:

primary presentation not chest pain

clear noncardiac cause of chest pain such as trauma life expectancy <1 year due to noncardiac pathology

Related Conditions & MeSH terms

• Chest Pain

Intervention

Other:
• no intervention
this is an observational study. no intervention is planned

Locations

Country	Name	City	State
United Kingdom	Royal Liverpool university hospital	Liverpool
United Kingdom	University Hospital Aintree	Liverpool

Sponsors (3)

Lead Sponsor	Collaborator
Aintree University Hospitals NHS Foundation Trust	Royal Liverpool University Hospital, University of Liverpool

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	incidence of Major adverse cardiac event for patients with HEART score<=3	adjudicated myocardial infarction, urgent or emergency coronary revascularisation, all-cause Death	6 weeks
Secondary	incidence of acute myocardial infarction for patients with HEART <=3	adjudicated centrally by 2 physicans blinded to heart scores and to colleagues score	6 weeks